Onchocerciasis
Case-control study Mahenge, Tanzania.
Year Started: 2021
HLA typing among cases and controls of onchocerciasis-associated epilepsy cases.
- Access:
- Open to applicants
- Type:
- Case-control
- Status:
- Completed
- Consent restrictions:
- No restrictions
| Associated Data Type | Procurement Timeframe |
|---|---|
| Biomarker datasets | 0 - 3 months |
| Clinical records | 0 - 3 months |
| Genomic datasets | 0 - 3 months |
| Survey data | 0 - 3 months |
| Participant Ethnicity | 0 - 3 months |
| Microbiological results | 0 - 3 months |
Both sexes
Adolescent (12 - 18 years)
101 - 500 donors
| Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Microscopic Assessment | % of Sample Set |
|---|---|---|---|---|---|
| Serum | -85°C to -60°C | Not applicable | 75% -99% | ||
| Dried whole blood | -85°C to -60°C | Not applicable | 75% -99% |
Onchocerciasis
Single versus Multiple Dose Ivermectin Regimen in Onchocerciasis-Infected Persons with Epilepsy Treated with Phenobarbital: A Randomized Clinical Trial in the Democratic Republic of Congo
Year Started: 2016
In October 2017, a 12-month clinical trial was initiated in rural Democratic Republic of Congo. PWE with onchocerciasis-associated epilepsy experiencing ≥2 seizures/month were randomly allocated to receive, over a one-year period, ivermectin once or thrice (group 1), while other onchocerciasis-infected PWE (OIPWE) were randomized to ivermectin twice or thrice (group 2). All participants also received anti-epileptic drugs.
- Access:
- Open to applicants
- Type:
- Clinical Trial
- Status:
- Completed
- Consent restrictions:
- Genetic analysis restriction
| Associated Data Type | Procurement Timeframe |
|---|---|
| Biomarker datasets | 0 - 3 months |
| Clinical records | 0 - 3 months |
| Followup records | 0 - 3 months |
| Freezer temperature logs | 0 - 3 months |
| Quality indicators | 0 - 3 months |
| Treatment records | 0 - 3 months |
| Participant Ethnicity | 0 - 3 months |
Both sexes
Adolescent (12 - 18 years)
11 - 100 donors
| Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Microscopic Assessment | % of Sample Set |
|---|---|---|---|---|---|
| Serum | -85°C to -60°C | Not applicable | 100% |